23 Jul, 2026
According to Straits Research, the global neuroscience antibodies and assays market size was valued at $3.95 billion in 2025 and is projected to reach $7.35 billion by 2034, at a CAGR of 7.16% during the forecast period 2026–2034.
The growth of the global neuroscience antibodies and assays market is strongly driven by the rising prevalence of neurological and neurodegenerative disorders worldwide. According to the World Health Organization, over 50 million people were living with dementia in 2024, a figure projected to exceed 80 million by 2035. This increasing neurological disease burden is fueling the adoption of advanced antibodies and assay tools, enabling early detection, biomarker discovery, and accelerated therapeutic development. In addition, the growing integration of high-throughput and digital technologies, such as multiplex immunoassays, single-cell proteomics, and AI-driven biomarker analysis, is creating significant market opportunities. These tools enhance research precision, allow for personalized therapeutic strategies, and facilitate ongoing monitoring of disease progression, making neuroscience research and diagnostics more effective and accessible.
However, the high costs associated with producing validated, highly specific antibodies and assays, coupled with the technical complexity of nervous system research, restrict widespread adoption in low and middle-income regions. Regulatory hurdles, including stringent validation and standardization requirements for novel reagents, also pose challenges for manufacturers and slow product launches. On the other hand, innovations in assay technologies, combination reagent platforms, and novel antibody engineering are enhancing the efficacy, reproducibility, and accessibility of neuroscience research tools.
North America dominated the market in 2025, accounting for 41.06% market share. This dominance is attributed to the strong presence of leading pharmaceutical and biotechnology companies in North America, coupled with substantial investments in neuroscience research. Advanced infrastructure and high adoption of validated antibodies and assay technologies collectively drive market growth in the region.
Asia Pacific is emerging as the fastest-growing region with a CAGR of 8.97% from 2026-2034. This growth is accelerated by research funding for neuroscience in countries such as China, India, and Japan. Expanding laboratory infrastructure, rising investments in academic and biotechnology research, and growing awareness of neurodegenerative diseases are accelerating the adoption of antibodies and assay technologies across the region.
sales@straitsresearch.com